Efficacy of Simplified Two Drug Kaletra Regimen vs. Kaletra Triple Drug Standard of Care Regimen in Treatment naïve HIV Infected Patients - Full Text View

Sponsor:	Abbott
Information provided by:	Abbott
ClinicalTrials.gov Identifier:	NCT00234910

Purpose

The purpose of this study is to obtain a preliminary assessment of the antiviral activity and tolerability of simplified Kaletra dual agent therapy as initial treatment for HIV infection, relative to a Kaletra three drug standard of care reference arm.

Condition	Intervention	Phase
HIV Infection	Drug: Tenofovir DF Drug: lopinavir/ritonavir with 2 Nucleoside RTIs	Phase III

Study Type:	Interventional
Study Design:	Treatment, Randomized, Open Label, Parallel Assignment, Safety/Efficacy Study
Official Title:	A Phase III, Open Label, Randomized, Comparative Study of the Antiviral Efficacy of ARV Therapy With Lopinavir/Ritonavir (LPV/r-Kaletra) in Combination With Tenofovir (TDF) Versus Standard of Care (Kaletra in Combination With 2 Nucleoside RTIs) in naïve-HIV-1 Positive Patients

Resource links provided by NLM:

MedlinePlus related topics: AIDS

Drug Information available for: Tenofovir Ritonavir Lopinavir Tenofovir disoproxil Tenofovir Disoproxil Fumarate

U.S. FDA Resources

Further study details as provided by Abbott:

Primary Outcome Measures:

Antiviral efficacy by HIV RNA [ Time Frame: 72 wks ] [ Designated as safety issue: No ]
Incidence of adverse events [ Time Frame: 72 wks ] [ Designated as safety issue: Yes ]

Secondary Outcome Measures:

Adherence and quality of life [ Time Frame: 72 wks ] [ Designated as safety issue: No ]

Enrollment:	152
Study Start Date:	January 2005
Study Completion Date:	June 2008
Primary Completion Date:	June 2007 (Final data collection date for primary outcome measure)

Arms	Assigned Interventions
A: Experimental 2 drug arm	Drug: Tenofovir DF TDF 300mg QD for 72 wks Drug: lopinavir/ritonavir with 2 Nucleoside RTIs LPV/rSGC 400/100mg BID + 2 nucleoside RTIs as prescribed by the Investigator for 72 wks
B: Active Comparator 3 drug arm, SOC	Drug: lopinavir/ritonavir with 2 Nucleoside RTIs LPV/rSGC 400/100mg BID + 2 nucleoside RTIs as prescribed by the Investigator for 72 wks

Eligibility

Ages Eligible for Study:	18 Years and older
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

HIV positive
>18 years of age
HIV RNA> 400 copies/mL
Any CD 4 cell count
Antiretroviral naïve
No acute illness

Exclusion Criteria:

-

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00234910

Locations

United States, Illinois
Global Medical Information-Abbott
Abbott Park, Illinois, United States, 60064

Sponsors and Collaborators

Abbott

Investigators

Study Director:

Umberto di Luzio Paparatti, MD

Abbott

More Information

No publications provided

Responsible Party:	Abbott ( Dr. Umberto di Luzio Paparatti, Medical Director Abbott Italy )
Study ID Numbers:	ITAL-04-002, EUDRACT 2004-000786-35, KALEAD
Study First Received:	September 13, 2005
Last Updated:	July 9, 2008
ClinicalTrials.gov Identifier:	NCT00234910 History of Changes
Health Authority:	Italy: National Monitoring Centre for Clinical Trials - Ministry of Health

Keywords provided by Abbott:

Lopinavir
Ritonavir
Kaletra

Tenofovir
HIV infection
Treatment Naive

Additional relevant MeSH terms:

Anti-Infective Agents
Communicable Diseases
Sexually Transmitted Diseases, Viral
Slow Virus Diseases
Molecular Mechanisms of Pharmacological Action
Infection
Reverse Transcriptase Inhibitors
Lopinavir
Anti-Retroviral Agents
Therapeutic Uses
Tenofovir
Retroviridae Infections
Nucleic Acid Synthesis Inhibitors
Tenofovir disoproxil
RNA Virus Infections

HIV Protease Inhibitors
Anti-HIV Agents
Immune System Diseases
Acquired Immunodeficiency Syndrome
Enzyme Inhibitors
Antiviral Agents
Immunologic Deficiency Syndromes
Pharmacologic Actions
Protease Inhibitors
Virus Diseases
HIV Infections
Ritonavir
Sexually Transmitted Diseases
Lentivirus Infections

ClinicalTrials.gov processed this record on November 09, 2009